ID: ALA1834563

Max Phase: Preclinical

Molecular Formula: C23H25N3O

Molecular Weight: 359.47

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN1CCN(c2ccccc2/C=C/C(=O)c2cn(C)c3ccccc23)CC1

Standard InChI:  InChI=1S/C23H25N3O/c1-24-13-15-26(16-14-24)21-9-5-3-7-18(21)11-12-23(27)20-17-25(2)22-10-6-4-8-19(20)22/h3-12,17H,13-16H2,1-2H3/b12-11+

Standard InChI Key:  PDSODPRWKCNFBT-VAWYXSNFSA-N

Associated Targets(Human)

RT-112 346 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 359.47Molecular Weight (Monoisotopic): 359.1998AlogP: 3.83#Rotatable Bonds: 4
Polar Surface Area: 28.48Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 7.10CX LogP: 4.17CX LogD: 3.99
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.52Np Likeness Score: -0.76

References

1. Martel-Frachet V, Kadri M, Boumendjel A, Ronot X..  (2011)  Structural requirement of arylindolylpropenones as anti-bladder carcinoma cells agents.,  19  (20): [PMID:21908193] [10.1016/j.bmc.2011.08.015]

Source